New 18-Month Exploratory Cardiac Results from HELIOS-A Phase 3 Study of Vutrisiran

New 18-Month Exploratory Cardiac Results from HELIOS-A Phase 3 Study of Vutrisiran

During the annual Heart Failure congress of the Heart Failure Association of the European Society of Cardiology, taking place May 21-24, 2022, we presented new 18-month results from the exploratory cardiac endpoints in the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis.

Read the press release
Garcia-Pavia, et al. “HELIOS-A: 18-Month Exploratory Cardiac Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis”



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.